ACC inhibitor alone or co-administered with a DGAT2 i non-alcoholic fatty liver disease: two parallel, placebo-c trials

Nature Medicine

27, 1836-1848

DOI: 10.1038/s41591-021-01489-1

Citation Report

#	Article	IF	Citations
1	Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?. Gastroenterology, 2023, 165, 5-10.	1.3	59
2	Phase IIa results for potential NAFLD therapy. Nature Reviews Endocrinology, 2022, 18, 2.	9.6	0
3	Targeting ACC for NASH resolution. Trends in Molecular Medicine, 2022, 28, 5-7.	6.7	9
4	An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Molecular Therapy, 2022, 30, 1329-1342.	8.2	18
5	Lipogenesis inhibitors: therapeutic opportunities and challenges. Nature Reviews Drug Discovery, 2022, 21, 283-305.	46.4	124
6	Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines, 2022, 10, 274.	3.2	22
7	New avenues for NASH therapy by targeting ACC. Cell Metabolism, 2022, 34, 191-193.	16.2	6
8	Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. Journal of Hepatology, 2022, 77, 219-236.	3.7	16
9	Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacologica Sinica, 2022, 43, 1180-1190.	6.1	22
10	Acetyl-CoA Carboxylases and Diseases. Frontiers in Oncology, 2022, 12, 836058.	2.8	52
11	Lipid alterations in chronic liver disease and liver cancer. JHEP Reports, 2022, 4, 100479.	4.9	69
13	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.9	18
14	Pharmacokinetics, Mass Balance, Metabolism, and Excretion of the Liver-Targeted Acetyl-CoA Carboxylase Inhibitor PF-05221304 (Clesacostat) in Humans. Xenobiotica, 2022, , 1-45.	1.1	1
15	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines, 2022, 10, 46.	3.2	10
16	Quantitative proteomics of HFD-induced fatty liver uncovers novel transcription factors of lipid metabolism. International Journal of Biological Sciences, 2022, 18, 3298-3312.	6.4	6
17	Lipid metabolism in T cell signaling and function. Nature Chemical Biology, 2022, 18, 470-481.	8.0	46
18	Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis. Annual Review of Nutrition, 2022, 42, 91-113.	10.1	20
19	Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Seminars in Liver Disease, 2022, 42, 379-400.	3.6	17

#	Article	IF	Citations
20	Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis, 2022, 355, 30-44.	0.8	7
21	Effects of Metabolism on Macrophage Polarization Under Different Disease Backgrounds. Frontiers in Immunology, 0, 13, .	4.8	10
22	A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease. Frontiers in Pharmacology, 0, 13, .	3.5	0
23	Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism: Clinical and Experimental, 2022, 134, 155264.	3.4	12
24	The postnatal resolution of developmental toxicity induced by pharmacological diacylglycerol acyltransferase 2 (DGAT2) inhibition during gestation in rats. Toxicological Sciences, 0, , .	3.1	0
25	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	90
26	Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice. Journal of Biological Chemistry, 2022, 298, 102401.	3.4	5
27	The mitochondrial fission protein Drp1 in liver is required to mitigate NASH and prevents the activation of the mitochondrial ISR. Molecular Metabolism, 2022, 64, 101566.	6.5	14
28	Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment. , 0, , .		1
29	Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease. World Chinese Journal of Digestology, 2022, 30, 735-742.	0.1	0
30	Association between de novo lipogenesis susceptibility genes and coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 2883-2889.	2.6	4
31	Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clinical Science, 2022, 136, 1347-1366.	4.3	56
32	FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Scientific Reports, 2022, 12, .	3.3	17
33	The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. International Journal of Molecular Sciences, 2022, 23, 12572.	4.1	20
34	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clinical and Molecular Hepatology, 2023, 29, 77-98.	8.9	27
35	Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Archives of Pharmacal Research, 2022, 45, 761-794.	6.3	5
36	Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation. Molecular Cell, 2022, 82, 4099-4115.e9.	9.7	20
37	Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis. Journal of Medicinal Chemistry, 2022, 65, 15000-15013.	6.4	11

#	Article	IF	Citations
38	Emerging pharmacological treatment options for MAFLD. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882211424.	3.2	4
39	Inulin intervention attenuates hepatic steatosis in rats via modulating gut microbiota and maintaining intestinal barrier function. Food Research International, 2023, 163, 112309.	6.2	17
40	Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis. European Endocrinology, 2022, 18, 148.	1.5	1
41	Progress of potential drugs targeted in lipid metabolism research. Frontiers in Pharmacology, 0, 13, .	3.5	5
42	Lian-Qu formula treats metabolic syndrome via reducing fat synthesis, insulin resistance and inflammation. Journal of Ethnopharmacology, 2023, 306, 116060.	4.1	4
43	A phase 2a, randomized, doubleâ€blind, placeboâ€controlled, threeâ€arm, parallelâ€group study to assess the efficacy, safety, tolerability and pharmacodynamics of <scp>PF</scp>â€06835919 in patients with nonâ€alcoholic fatty liver disease and type 2 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 992-1001.	4.4	6
44	Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice. American Journal of Physiology - Endocrinology and Metabolism, 2023, 324, E187-E198.	3.5	3
45	Rational combination therapy for NASH: Insights from clinical trials and error. Journal of Hepatology, 2023, 78, 1073-1079.	3.7	7
46	Lipidomics analysis in drug discovery and development. Current Opinion in Chemical Biology, 2023, 72, 102256.	6.1	9
48	Role of hepatic peroxisome proliferator-activated receptor Î³ in non-alcoholic fatty liver disease. Journal of Endocrinology, 2023, 257, .	2.6	4
49	Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology. Clinical Therapeutics, 2023, 45, 55-70.	2.5	9
50	Recent updates on targeting the molecular mediators of NAFLD. Journal of Molecular Medicine, 2023, 101, 101-124.	3.9	3
51	Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease. Journal of Ethnopharmacology, 2023, 310, 116418.	4.1	2
52	Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate. Journal of Lipid Research, 2023, 64, 100339.	4.2	2
53	Targeting lipid metabolism with natural products: A novel strategy for gastrointestinal cancer therapy. Phytotherapy Research, 2023, 37, 2036-2050.	5.8	6
54	Targeting acetyl-CoA carboxylase 1 for cancer therapy. Frontiers in Pharmacology, 0, 14, .	3.5	5
55	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. Cardiology in Review, 0, Publish Ahead of Print, .	1.4	1
56	Challenges and opportunities in NASH drug development. Nature Medicine, 2023, 29, 562-573.	30.7	51

#	Article	IF	Citations
57	Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring. Hepatology Communications, 2023, 7, .	4.3	4
59	Current, emerging, and potential therapies for non-alcoholic steatohepatitis. Frontiers in Pharmacology, 0, 14, .	3.5	6
60	Malonylation of Acetyl-CoA carboxylase 1 promotes hepatic steatosis and is attenuated by ketogenic diet in NAFLD. Cell Reports, 2023, 42, 112319.	6.4	2
61	Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease. Cell, 2023, 186, 1968-1984.e20.	28.9	11
62	Clinical Trial Landscape in NASH. Clinical Gastroenterology and Hepatology, 2023, 21, 2001-2014.	4.4	21
63	An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. Journal of Hepatology, 2023, 79, 552-566.	3.7	47
64	Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies. Frontiers in Medicine, 0, 10, .	2.6	3
65	Erianin alleviated liver steatosis by enhancing Nrf2-mediated VE-cadherin expression in vascular endothelium. European Journal of Pharmacology, 2023, 950, 175744.	3.5	2
66	Galanin ameliorates liver inflammation and fibrosis in mice by activating AMPK/ACC signaling and modifying macrophage inflammatory phenotype. Frontiers in Immunology, 0, 14, .	4.8	3
67	Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat. Chemical Research in Toxicology, 0, , .	3.3	0
69	Physiological and pathological roles of lipogenesis. Nature Metabolism, 2023, 5, 735-759.	11.9	21
70	Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	13
71	The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	10
72	Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. Nutrients, 2023, 15, 2323.	4.1	3
73	Lipid droplet biogenesis and functions in health and disease. Nature Reviews Endocrinology, 2023, 19, 443-459.	9.6	49
74	Metabolomics Reveals Gut Microbiota Contribute to PPARÎ± Deficiency-Induced Alcoholic Liver Injury. Journal of Proteome Research, 2023, 22, 2327-2338.	3.7	2
75	Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention. Nutrition and Metabolism, 2023, 20, .	3.0	1
77	Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition. Journal of Clinical Investigation, 0, , .	8.2	2

#	Article	IF	Citations
78	Intracellular spatiotemporal metabolism in connection to target engagement. Advanced Drug Delivery Reviews, 2023, , 115024.	13.7	0
79	Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition. JAMA Cardiology, 0, , .	6.1	0
80	Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina (Lithuania), 2023, 59, 1789.	2.0	0
81	Bioactivation and reactivity research advances â€“ 2022 year in reviewâ€¡. Drug Metabolism Reviews, 0, , 1-34.	3.6	0
82	Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention. Hepatology Communications, 2023, 7, .	4.3	1
83	Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery. Journal of Controlled Release, 2023, 363, 415-434.	9.9	3
84	A bacteria-derived tetramerized protein ameliorates nonalcoholic steatohepatitis in mice via binding and relocating acetyl-coA carboxylase. Cell Reports, 2023, 42, 113453.	6.4	0
85	Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease. Livers, 2023, 3, 687-708.	1.9	0
86	Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. Journal of Hepatology, 2024, 80, 362-377.	3.7	1
87	In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions. Liver Research, 2023, 7, 285-295.	1.4	0
88	Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic. Frontiers in Medicine, 0, 10, .	2.6	1
89	Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use. Nature Communications, 2024, 15, .	12.8	2
90	The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7. Cardiovascular Diabetology, 2024, 23, .	6.8	1
91	TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase. Journal of Clinical Investigation, 2024, 134, .	8.2	2
92	Extracellular vesicles derived from liver sinusoidal endothelial cells inhibit the activation of hepatic stellate cells and Kupffer cells in vitro. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2024, 1870, 167020.	3.8	0
93	Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond. Biomedicines, 2024, 12, 397.	3.2	0
94	DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER. Cell Metabolism, 2024, 36, 617-629.e7.	16.2	0
95	Investigation of pharmacokinetic drug interaction between clesacostat and <scp>DGAT2</scp> inhibitor ervogastat in healthy adult participants. Clinical and Translational Science, 2024, 17, .	3.1	0

#	Article	IF	Citations
96	Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability. Cell Metabolism, 2024, 36, 1088-1104.e12.	16.2	0
97	Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease. Trends in Pharmacological Sciences, 2024, 45, 319-334.	8.7	0